P535: Effectiveness of upadacitinib in patients with Ulcerative Colitis: a real-life, multicenter, Italian reportECCO'24Year: 2024
Authors: Teani, I.(1)*;Bevilacqua, N.(1);Gabbiadini, R.(2);Bezzio, C.(3);Ferronato, A.(4);Saibeni, S.(3);Armuzzi, A.(2);Comberlato, M.(1);Desideri, F.(1);
(1)San Maurizio Hospital, Gastroenterology Department, Bolzano, Italy;(2)Humanitas Research Hospital-IRCCS, IBD Center, Milano, Italy;(3)Rho Hospital- ASST Rhodense, Gastroenterology Unit, Milano, Italy;(4)Santorso Hospital- AULSS 7, Digestive Endoscopy, Vicenza, Italy;
P536: Outcome of colorectal cancer surveillance in paediatric inflammatory bowel disease: Time for new guidelines?ECCO'24Year: 2024
Authors: Vermeer, E.(1,2,3)*;Palsma, C.J.(1);Gorter, R.R.(4);de Boer, N.K.(2,5);de Jonge, R.(6);Roelofs, J.J.(7);de Meij, T.G.J.(1,2,3);
(1)Amsterdam UMC, Paediatric Gastroenterology, Amsterdam, The Netherlands;(2)Amsterdam UMC, Amsterdam Gastroenterology- Endocrinology and Metabolism Research Institute, Amsterdam, The Netherlands;(3)Amsterdam UMC, Amsterdam Reproduction and Development Research Institute, Amsterdam, The Netherlands;(4)Amsterdam UMC, Paediatric Surgery, Amsterdam, The Netherlands;(5)Amsterdam UMC, Gastroenterology and Hepatology, Amsterdam, The Netherlands;(6)Amsterdam UMC, Laboratory Medicine, Amsterdam, The Netherlands;(7)Amsterdam UMC, Pathology, Amsterdam, The Netherlands;
P537: Analysis of immunological VAriables in ex vivo Tofacitinib-treated human biopsies from Active ulcerative colitis patients to predict clinical Response (the AVATAR study)ECCO'24Year: 2024
Authors: Onali, S.(1);Di Petrillo, A.(2);Soddu, P.(2);Ibba, I.(3);Demurtas, M.(3);Raho, N.(2);Morrocchi, E.(4);Amodio, D.(4);Palma, P.(4);Milenkovic, S.(5);Ceccarelli, M.(5);FantiniMD- PhD, M.C.(6)*;
(1)University of Cagliari, Department of Medical Science and Public Health, Rome, Italy;(2)University of Cagliari, Department of Medical Science and Public Health, Cagliari, Italy;(3)University Hospital of Cagliari, Gastroenterology Unit, Cagliari, Italy;(4)University of Rome Tor Vergata, Department of Systems Medicine, Rome, Italy;(5)University of Cagliari, Department of Physics, Cagliari, Italy;(6)University of Cagliari, of Medical Science and Public Health, Monserrato, Italy;
P538: Platelet-rich stroma during surgery for treatment-refractory perianal fistulizing Crohn’s disease: long-term outcomes of a pilot studyECCO'24Year: 2024
Authors: Bak, M.(1)*;Witjes, C.(2);Arkenbosch, J.(3);Dwarkasing, R.(4);van Dongen, J.(5);Fuhler, G.(3);Schouten, R.(6);van der Woude, J.(3);de Vries, A.(3);van Ruler, O.(7);
(1)Erasmus University Medical Center, Department of Gastroenterology and Hepatology, Rotterdam, The Netherlands;(2)IJsselland Hospital, Department of Surgery, Cappelle aan den IJssel, The Netherlands;(3)Erasmus University Medical Center Rotterdam, Department of Gastroenterology and Hepatology, Rotterdam, The Netherlands;(4)Erasmus University Medical Center Rotterdam, Radiology, Rotterdam, The Netherlands;(5)University Medical Center Utrecht, Department of Plastic- Reconstructive and Hand Surgery, Utrecht, The Netherlands;(6)IJsselland Hospital, Department of Surgery, Capelle aan den IJssel, The Netherlands;(7)IJselland Hospital, Department of Surgery, Capelle aan den IJssel, The Netherlands;
P539: Assessment of VEdolizumab aNd Ustekinumab in Elderly patients with Crohn’s disease (CD): the IG-IBD AVENUE study.ECCO'24Year: 2024
Authors: Viola, A.(1);Ventimiglia, M.(2);Sparacino, A.(3);Orlando, A.(4);D@E@Antono, E.(4);De Vivo , S.(4);Scaldaferri, F.(5);Pugliese, D.(5);Varca, S.(6);Ribaldone, D.G.(7);Armandi, A.(7);Balestrieri , P.(8);Castiglione, F.(9);Savarino, E.V.(10);Cappello, M.(11);Viganò, C.(12);Mocci, G.(13);Allocca, M.(14);Principi, M.B.(15);Soriano, A.(16);Onali, S.(17);Bodini, G.(18);Riguccio, G.(19);Festa, S.(20);Bertani, L.(21);Checchin, D.(22);Caprioli, F.A.(23);Fries, W.(24)*;
(1)IBD-Unit- Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy;(2)Directorate General of Medical Devices and Pharmaceutical service, Italian Ministry of Health-, Milan, Italy;(3)IBD-Unit- Department of Clinical and Experimental Medicine- University of Messina. Head IBD Clinic- Gastroenterology Section- Promise, University of Palermo, Palermo, Italy;(4)Riuniti Villa Sofia–Cervello Hospital, IBD Unit Palermo, Palermo, Italy;(5)CEMAD - IBD UNIT- Dipartimento di Scienze Mediche e Chirurgiche- Fondazione Policlinico Universitario Gemelli- IRCCS- Dipartimento di Medicina e Chirurgia Traslazionale, Università Cattolica del Sacro Cuore, Roma, Italy;(6)CEMAD - IBD UNIT- Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario Gemelli- IRCCS, Roma, Italy;(7)Division of Gastroenterology- Department of Medical Sciences, University of Turin, Torino, Italy;(8)Unit of Gastroenterology, Campus Bio-Medico University, Roma, Italy;(9)Gastroenterology- Department of Clinical Medicine and Surgery, University Federico II of Naples, Napoli, Italy;(10)Department of Surgery- Oncology and Gastroenterology, University of Padova, Padova, Italy;(11)Head IBD Clinic- Gastroenterology Section- Promise, University of Palermo, Palermo, Italy;(12)Department of Gastroenterology- and Center for Autoimmune Liver Diseases- European Reference Network on Hepatological Diseases ERN RARE-LIVER- Fondazione IRCCS San Gerardo dei Tintori, University of Milano-Bicocca School of Medicine, Monza, Italy;(13)Gastroenterologia, ARNAS G. Brotzu, Cagliari, Italy;(14)IRCCS OSPEDALE San Raffaele- Gastroenterology and Endoscopy, IBD Center, Milano, Italy;(15)Gastroenterology Unit Department of Precision and Regenerative Medicine and Ionian Area DiMePRe-J., University of Bari, Bari, Italy;(16)IBD Center- Internal Medicine Department- Arcispedale S. Maria Nuova, IRCCS Reggio Emilia, Reggio Emilia, Italy;(17)Dept of Medical Science and Public Health- Gastroenterology Unit, University of Cagliari, Cagliari, Italy;(18)IRCCS Policlinico San martino- Gastrointestinal Unit- Department of Internal Medicine, University of Genoa, Genova, Italy;(19)UOSD Malattie Infiammatorie Croniche intestinali, Ospedale Santa Maria del Prato, Feltre, Italy;(20)IBD Unit, @D@San Filippo Neri@D@ Hospital, Roma, Italy;(21)Tuscany North West ASL- Pontedera Hospital, Dept of General Surgery and Gastroenterology, Pontedra, Italy;(22)Gastrointestinal Unit, Ospedale dell@E@Angelo, Venezia, Italy;(23)Gastroenterology and Endoscopy Unit- Fondazione IRCCS Cà Granda- Ospedale Maggiore Policlinico, Department of Pathophysiology and Transplantation- University of Milan, Milano, Italy;(24)IBD-Unit- Dept of Clinical and Experimental Medicine, University of Messina, Messina, Italy;AVENUE Study Group: Michele Francesco Chiappetta Giulio Calabrese Piera Melatti Giorgia Orrù Francesca Maria Onidi Giorgia Orrù Maria Napolitano Francesca Onnis
P540: Non-serious adverse events in patients with ulcerative colitis receiving etrasimod: An analysis of the phase 2 OASIS and phase 3 ELEVATE UC 52 and ELEVATE UC 12 clinical trialsECCO'24Year: 2024
Authors: Lees, C.(1,2)*;Torres, J.(3,4,5);Leung, Y.(6);Vermeire, S.(7);Fellmann, M.(8);Modesto, I.(9);McDonnell, A.(10);Lazin, K.(8);Keating, M.(9);Goetsch, M.(8);Wu, J.(11);Loftus Jr, E.V.(12);
(1)University of Edinburgh, Institute of Genetics & Molecular Medicine, Edinburgh, United Kingdom;(2)Western General Hospital- NHS Lothian, Edinburgh IBD Unit, Edinburgh, United Kingdom;(3)Hospital Beatriz Ângelo, Division of Gastroenterology, Loures, Portugal;(4)., Faculdade de Medicina- Universidade de Lisboa, Lisbon, Portugal;(5)Hospital da Luz, Division of Gastroenterology, Lisbon, Portugal;(6)University of British Columbia, Department of Medicine- Department of Gastroenterology, Vancouver- BC, Canada;(7)University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium;(8)., Pfizer AG, Zürich, Switzerland;(9)., Pfizer Inc, New York- NY, United States;(10)., Pfizer Ltd, Sandwich, United Kingdom;(11)., Pfizer Inc, Cambridge- MA, United States;(12)Mayo Clinic College of Medicine and Science, Division of Gastroenterology and Hepatology, Rochester- MN, United States;
P541: Long-term follow-up results of darvadstrocel for complex perianal fistulas in patients with Crohn@E@s disease: 3-year outcomes from a Japanese phase 3 studyECCO'24Year: 2024
Authors: Uchino, M.(1)*;Ikeuchi, H.(1);Ito, T.(2);Sakakibara, Y.(3);Nakaya, R.(3);Yamaguchi, T.(3);
(1)Hyogo Medical University, Department of Gastroenterological Surgery- Division of Inflammatory Bowel Disease, Nishinomiya, Japan;(2)Sapporo Higashi Tokushukai Hospital, IBD center, Sapporo, Japan;(3)Takeda Pharmaceutical Company Limited, Takeda Development Center, Osaka, Japan;
P542: Clinical decision support tool guided selective intensive induction strategy of ustekinumab in patients with Crohn’s disease: real-world evidenceECCO'24Year: 2024
Authors: Li, Q.(1)*;Tang, J.(1);Shi, L.(2);Lv, X.(3);Chen, W.(4);Guo, Q.(1);Li, M.(1);Gao, X.(1);Chao, K.(1);
(1)The Sixth Affiliated Hospital- Sun Yat-sen University, Department of Gastroenterology, guangzhou, China;(2)The Sixth Affiliated Hospital- Sun Yat-sen University, Center for Clinical Research, Guangzhou, China;(3)The First Affiliated Hospital of Guangxi Medical University, Department of Gastroenterology, Guangxi, China;(4)Peking University Shenzhen Hospital, Department of Gastroenterology, Shenzhen, China;
P543: Patients in trials of moderate-to-severe UC who are exposed to placebo are more likely to suffer harm than those receiving active treatment: The lack of clinical equipoise in traditional study designsECCO'24Year: 2024
Authors: Fine, Z.(1)*;Fear, E.N.(1);St-Pierre, J.(1);Klein, J.A.(1);Choi, N.K.(1);Rubin, D.T.(1,2,3);
(1)University of Chicago, Section of Gastroenterology- Hepatology and Nutrition, Chicago, United States;(2)University of Chicago, Inflammatory Bowel Disease Center, Chicago, United States;(3)University of Chicago, Maclean Center for Clinical Medical Ethics, Chicago, United States;
P544: Ustekinumab safety and effectiveness in ulcerative colitis patients: results from a large real-life study.ECCO'24Year: 2024
Authors: MocciMD FRCP, G.(1)*;Scaldaferri, F.(2);Pugliese, D.(2);Savarino, E.(3);Bodini, G.(4);Cuomo, A.(5);Donnarumma, L.(5);Maconi, G.(6);Cataletti, G.(6);Rodino, S.(7); Sebkova, L.(7);Ferronato, A.(8);Gaiani , F.(9);Marzo , M.(10);Luppino, I.(11);Paese, P.(11);Elisei, W.(12);Monterubbianesi, R.(12);Faggiani, R.(12);Napolitano, D.(2);Grossi, L.(13);Serio, M.(14);Scarcelli, A.(14);Lorenzetti, R.(15);Allegretta , L.(16);Rocco, G.(17);Zampaletta, C.(17);Bolognini, L.(18);Meucci, C.(19);Colucci, R.(20);Tonti, P.(21);Della Valle , N.(22);Piga, R.(23);Forti, G.(24);Onidi, F.M.(1);Usai Satta, P.(1);Picchio, M.(25);Papa, A.(2);Tursi, A.(26);
(1)Arnas- Brotzu Hospital, Department of Internal Medicine- Gastroenterology Unit, Cagliari, Italy;(2)Policlinico Universitario “A. Gemelli” Foundation- IRCCS, Digestive Diseases Centre CEMAD- Department of Medical and Surgical Sciences, Roma, Italy;(3)Azienda Ospedale-Università di Padova AOUP, Gastroenterology Unit, Padua, Italy;(4)IRCCS @D@San Martino@D@ Hospital- University of Genoa, Department of Internal Medicine and Medical Specialties- Division of Gastroenterology-, Genova, Italy;(5)“Umberto I” Hospital- Nocera Inferiore SA, 7 Division of Gastroenterology-, Nocera Inferiore, Italy;(6)“L. Sacco” University Hospital, Gastroenterology Unit- Department Biomedical and Clinical Sciences, Milano, Italy;(7)“Ciaccio-Pugliese” Hospital, Division of Gastroenterology, Catanzaro, Italy;(8)ULSS7 Pedemontana, Digestive Endoscopy Unit-, Santorso, Italy;(9)University of Parma, Gastroenterology and Endoscopy Unit- Department of Medicine and Surgery, Parma, Italy;(10)“Veris-Delli Ponti” Hospital- Scorrano, Division of Gastroenterology-, Scorrano LE, Italy;(11)“Annunziata” Hospital, Division of Gastroenterology, Cosenza, Italy;(12)A.O. “S. Camillo-Folanini”, Division of Gastroenterology, Roma, Italy;(13)“Spirito Santo” Hospital- “G d@E@Annunzio” University, Gastroenterology Unit, Pesca, Italy;(14)“San Salvatore” Hospital, Division of Gastroenterology, Pesaro, Italy;(15)“Nuovo Regina Margherita” Territorial Hospital, Division of Gastroenterology, Roma, Italy;(16)“Santa Caterina Novella” Hospital, Division of Gastroenterology-, Galatina LE, Italy;(17)“Belcolle” Hospital, Division of Gastroenterology, Viterbo, Italy;(18)A.O. “Ospedali Riuniti”- Ancona- Italy, Division of Digestive Diseases- Digestive Endoscopy and Inflammatory Bowel Diseases, Ancona, Italy;(19)“T. Maresca” Hospital, Division of Gastroenterology, Torre del Greco NA, Italy;(20)“San Matteo degli Infermi” Hospital, Digestive Endoscopy Unit, Spoleto PG, Italy;(21)“A. Perrino” Hospital, Division of Gastroenterology, Brindisi, Italy;(22)A.O. “Ospedali Riuniti, Division of Gastroenterology, Foggia, Italy;(23)“S. Pertini” Hospital, Division of Gastroenterology- IBD Unit-, Roma, Italy;(24)“S. Maria Goretti” Hospita, Division of Digestive Endoscopy, Latina, Italy;(25)“P. Colombo” Hospital- ASL Roma 6, Division of General Surgery, Velletri Roma, Italy;(26)Territorial Gastroenterology Service- ASL BAT, Territorial Gastroenterology Service, Andria, Italy;
P545: Long-term efficacy of ozanimod up to 3 years in patient response subgroups identified using group-based trajectory modellingECCO'24Year: 2024
Authors: Schreiber, S.W.(1)*;Feagan, B.G.(2);Sands, B.E.(3);Rieder, F.(4);Torres, J.(3,5,6,7);Liu, Z.(8);Jain, A.(8);Poehler, A.M.(9);Wu, H.(8);Osterman, M.T.(8);Abreu, M.T.(10);Dulai, P.S.(11);
(1)Department of Internal Medicine I- University Hospital Schleswig-Holstein- Kiel University, Internal Medicine I, Kiel, Germany;(2)Robarts Research Institute- Western University, Gastroenterology, London, Canada;(3)Icahn School of Medicine at Mount Sinai, Gastroenterology, New York, United States;(4)Department of Gastroenterology- Hepatology- and Nutrition- Digestive Disease Institute- Cleveland Clinic, Gastroenterology- Hepatology- and Nutrition, Cleveland, United States;(5)Division of Gastroenterology- Hospital da Luz- Hospital Beatriz Ângelo- and Faculdade de Medicina- Universidade de Lisboa, Gastroenterology, Lisbon, Portugal;(6)Division of Gastroenterology- Hospital Beatriz Ângelo, Gastroenterology, Lisbon, Portugal;(7)Faculdade de Medicina- Universidade de Lisboa, Gastroenterology, Lisbon, Portugal;(8)Bristol Myers Squibb, n/a, Princeton, United States;(9)Bristol Myers Squibb, n/a, Munich, Germany;(10)University of Miami Miller School of Medicine, Gastroenterology, Miami, United States;(11)Feinberg School of Medicine- Northwestern University, Gastroenterology and Hepatology, Chicago, United States;
P547: Improved clinical and radiologic healing of Crohn’s perianal fistulas using a novel coordinated care model optimising medical and surgical treatments: A prospective real-world observational studyECCO'24Year: 2024
Authors: De Gregorio, M.(1,2)*;Winata, L.S.(3);Hartley, I.(1,2);Behrenbruch, C.C.(2,4);Connor, S.J.(5,6);D‘Souza, B.(2,7);Basnayake, C.(1,2);Guerra, G.R.(4,8);Johnston, M.J.(4);Kamm, M.A.(1,2);Keck, J.O.(4);Lust, M.(1);Niewiadomski, O.(1);Ong, E.J.S.(4);Schulberg, J.D.(1,2);Srinivasan, A.(9,10);Sutherland, T.(2,3);Woods, R.J.(4);Wright, E.K.(1,2);Connell, W.R.(1);Thompson, A.J.(1,2);Ding, N.S.(1,2);
(1)St Vincent@E@s Hospital Melbourne, Gastroenterology, Fitzroy, Australia;(2)University of Melbourne, Medicine, Parkville, Australia;(3)St Vincent@E@s Hospital Melbourne, Medical Imaging, Fitzroy, Australia;(4)St Vincent@E@s Hospital Melbourne, Colorectal Surgery, Fitzroy, Australia;(5)Liverpool Hospital Sydney, Gastroenterology, Liverpool, Australia;(6)University of New South Wales South West Sydney Clinical Campuses, Medicine and Health, Sydney, Australia;(7)Northern Hospital, Colorectal Surgery, Epping, Australia;(8)University of Melbourne, Surgery, Parkville, Australia;(9)Austin Health, Gastroenterology, Heidelberg, Australia;(10)Eastern Health, Gastroenterology, Box Hill, Australia;
P548: Ustekinumab shows favourable safety profile and drug persistence rates in patients with Crohn’s Disease – results from a tertiary IBD centreECCO'24Year: 2024
Authors: Snehali, M.(1,2,3,4)*;Ahmed, A.(1);Ghosh, S.(2);Iacucci, M.(2,4,5);Shivaji, U.N.(1,4,5,6);
(1)University Hospitals Birmingham NHS Foundation Trust- Birmingham- UK, Gastroenterology, Birmingham, United Kingdom;(2)APC Microbiome Ireland- College of Medicine and Health- University College Cork- Ireland, Medicine, Cork, Ireland;(3)NH Narayana Health- Bangalore- India, Clinical Research, Bangalore, India;(4)Institute of Immunology and Immunotherapy- University of Birmingham- UK, Immunology and Immunotherapy, Birmingham, United Kingdom;(5)National Institute for Health Research NIHR Birmingham Biomedical Research Centre- University of Birmingham and University Hospitals Birmingham NHS Foundation Trust- UK, Biomedical Research, Birmingham, United Kingdom;(6)Mazumdar-Shaw Medical Centre- A Unit of NH Narayana Health- Bangalore- India, Gastroenterology, Bangalore, India;
P549: Liver stiffness assessed with TE-CAP tends to increase with longer duration of disease in Crohn’s disease: A prospective cohort study for the evaluation of hepatic abnormalities in inflammatory bowel diseaseECCO'24Year: 2024
Authors: Moon, W.(1)*;Seo, K.I.(1);Park, H.J.(1);Lee, J.W.(1);Yun, B.C.(1);Park, S.J.(1);Kim, J.H.(1);Park, M.I.(1);Kim, S.E.(1);Jung, K.(1);
(1)Kosin University College of Medicine, Crohn’s Disease and Ulcerative Colitis Clinic- Division of Gastroenterology and Hepatology- Department of Internal Medicine, Busan, Korea- Republic Of;
P550: Short and long-term outcomes after acute severe ulcerative colitis in adults: A 12 year Canadian experience in the post biologic eraECCO'24Year: 2024
Authors: Vuyyuru, S.(1)*;Alphonsus, L.(2);De Silva, T.A.(2);Archer, M.(3);Solitano, V.(4);Guizzetti, L.(5);Crowley, E.(6);Ponich, T.(7);Beaton, M.(7);Gregor, J.(8);Yan, B.(8);Sey, M.(9);Jairath, V.(10);
(1)Nottingham University Hospitals NHS trust, Gastroenterology, Nottingham, United Kingdom;(2)Western University- Canada, Schulich School of Medicine and Dentistry, London, Canada;(3)Western University- Canada, Lawson Health Research Institute, London, Canada;(4)Humanitas University- Italy, Department of Biomedical Sciences, Milan, Italy;(5)Independent researcher, Independent researcher, London, Canada;(6)Western University- Children’s Hospital- London Health Sciences Centre- Canada, Division of Pediatric Gastroenterology, London, Canada;(7)Schulich School of Medicine- Western University- Canada., Department of Medicine- Division of Gastroenterology, London, Canada;(8)Schulich School of Medicine- Western University- Canada., Department of Medicine- Division of Gastroenterology-, London, Canada;(9)Schulich School of Medicine- Western University- Canada., awson Health Research Institute- Department of Medicine- Division of Gastroenterology-, London, Canada;(10)Schulich School of Medicine- Western University- Canada, Lawson Health Research Institute- Department of Epidemiology and Biostatistics- Department of Medicine- Division of Gastroenterology, London, Canada;
P551: Benefit–risk trade-offs and patient preferences for therapy selection in Ulcerative Colitis: a multi-country preference studyECCO'24Year: 2024
Authors: Gisbert, J.P.(1,2);Schreiber, S.(3);Siegel, C.A.(4,5);Magro, F.(6);Jus, A.(7);Whichello, C.(8);Michaels-Igbokwe, C.(9);Heidenreich, S.(8);Oortwijn, A.(10);Vermeire, S.(11)*;
(1)Hospital Universitario de La Princesa- Instituto de Investigación Sanitaria Princesa IIS-Princesa- Universidad Autónoma de Madrid UAM, Gastroenterology department, Madrid, Spain;(2)Carlos III Health Institute, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas CIBERehd, Madrid, Spain;(3)Kiel University- University Hospital Schleswig-Holstein, Department of Internal Medicine I, Kiel, Germany;(4)Dartmouth Hitchcock Medical Center, Inflammatory Bowel Disease Center- Section of Gastroenterology & Hepatology, Lebanon- NH, United States;(5)Geisel School of Medicine at Dartmouth, The Dartmouth Institute for Health Policy and Clinical Practice, Hanover- NH, United States;(6)University of Porto, CINTESIS@RISE- Faculty of Medicine, Porto, Portugal;(7)Galapagos B.V., Evidence Generation, Leiden, The Netherlands;(8)Evidera Inc., Patient-Centered Research, London, United Kingdom;(9)Evidera Inc., Patient-Centered Research, Montreal- QC, Canada;(10)Galapagos B.V., Medical Affairs, Leiden, The Netherlands;(11)UZ Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium;
P552: Clinical factors associated with ustekinumab therapy persistence in a refractory Crohn’s disease cohortECCO'24Year: 2024
Authors: Corcoran, R.(1)*;Breslin, N.(2);Ryan, B.(2);O@E@Connor, A.(2);O@E@Donnell, S.(2);McKiernan, S.(1);MacCarthy, F.(1);Dunne, C.(1);Hartery, K.(1);McNamara, D.(2);Kevans, D.(1);
(1)St James@E@s Hospital, Department of Gastroenterology, Dublin 8, Ireland;(2)Tallaght University Hospital, Department of Gastroenterology, Dublin 24, Ireland;Trinity Academic Gastroenterology Group (TAAG)
P553: The safety and efficacy of adalimumab 80mg weekly as maintenance therapy in pediatric Crohn’s DiseaseECCO'24Year: 2024
Authors: Cohen-Sela , E.(1);Weintraub , Y.(1);Yerushalmy-Feler , A.(2);Orlanski-Meyer , E.(3);Nassar , R.(4);Magen-Rimon , R.(5);Shamir , R.(1);Shouval , D.S.(1);Matar , M.(1)*;
(1)Schneider Children@E@s Medical Center and the Faculty of Medicine- Tel Aviv University, Institute of Gastroenterology- Nutrition and Liver Diseases, Petach Tikva, Israel;(2)Dana-Dwek Children@E@s Hospital, Pediatric Gastroenterology Institute, Tel Aviv, Israel;(3)Shaare Zedek Medical Center, The Institute of Gastroenterology- Nutrition and Liver Diseases, Jerusalem, Israel;(4)Soroka Medical Center, Pediatric Gastroenterology Unit, Beer Sheva, Israel;(5)Rambam Medical Center, Pediatric Gastroenterology Unit, Haifa, Israel;
